[Comparison of the therapeutic efficacy and tolerability of acemetacin and tolmetin (author's transl)].
In a controlled double blind study the therapeutic efficacy and tolerability of [1-(p-chlorobenzoyl)-5-methoxy-2-methylindol-3-acetoxy] acetic acid (acemetacin, TV 1322, Rantudil¿) and tolmetin were compared in 40 patients suffering from acute and subacute painful irritant conditions in the spinal area and joints. The maximal duration of the study was 20 days. In the case of acemetcin the daily dose was 90 mg and in the case of tolmetin it was 600 mg. The clinical symptoms kinesalgia, pain caused by pressure, and functional impairment were significantly improved by both acemetacin and tolmetin. A comparison of the two therapy groups did not reveal any difference. Also a statistical comparison of the evaluations of the therapeutic efficacy by the physician did not reveal any significant difference, although the assessment "very good" occurred twice as frequently in the acemetacin group (13 out of 20) as in the tolmetin group (6 out of 20). In only one patient treated with tolmetin undesired drug reactions occurred. These resulted in discontinuation of the therapy. No side effects occurred in the acemetacin group. Acemetacin, which in experimental animal investigations not only showed an antiinflammatory but also an analgesic effect, is according to the results of our study also suitable for the therapy of symptoms in which the analgesic efficacy of a drug decisively influences the therapeutic success.